Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
2024年2月22日 - 6:15AM
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted
oncology company forging new territory in patient-directed cancer
treatment, today announced the resignation of Dr. Sergio Santillana
and the appointment of Dr. Caroline Germa as Chief Medical Officer.
Her addition comes at a pivotal time with the Company’s focus on
its clinical programs, IK-930 and IK-595, underscoring Ikena’s
commitment to driving innovation in the targeted oncology space.
“Our clinical team is firing on all cylinders to bring the right
patients into our ongoing IK-930 and IK-595 studies, and to
collaborate with our investigators to learn as much as we can from
these two novel Phase I programs. Dr. Germa’s leadership and
experience in clinical drug development, in both the biotech space
and the large pharma world, will be instrumental to our development
effort and strategy, as we set both of our programs up for
success,” said Mark Manfredi, Ph.D., Chief Executive Officer of
Ikena. “We are confident that Dr. Germa’s contributions will
continue to broaden patient access to our programs and, in turn,
drive value for our investors and stakeholders, as we remain on
track to deliver a clinical update in the second half of this
year.”
Dr. Germa is an accomplished medical oncologist and clinical
development leader with over 25 years of pharmaceutical experience
across the spectrum of drug development, from early clinical trials
to late phase and registrational studies. Prior to Ikena, Dr. Germa
served as the EVP, Global Medicine Development, and Chief Medical
Officer at Transcenta Therapeutics, where she played a pivotal role
in shaping strategic goals for the company’s oncology and
non-oncology portfolio, ensuring successful execution across all
clinical development functions. Previously, Dr. Germa held senior
leadership positions at global pharmaceutical companies such as
AstraZeneca as Vice President and Head of Oncology Early
Development Clinical Group, Bristol Myers Squibb as Development
Team Lead for NKTR214, and Novartis where in particular she led the
development and registration of KISQALI®, solidifying her
reputation as a trailblazer in advancing oncology care in the
relentless pursuit of a cure for cancer. Dr. Germa earned her
Medical Doctor degree and board certification in medical oncology
at the University of Lille, a degree in immunology from the
University of Lille and a degree in health economics from Paris
Diderot University in France.
Dr. Germa added, “I am thrilled to be joining Ikena at a time
when it is primed for clinical inflection across the pipeline. The
opportunity to work in a first-in-class program like IK-930, in a
novel pathway like Hippo, is one that does not come often. In
addition to that, I am deeply motivated by the work the team has
done to solve what is missing for RAS and RAF mutant cancer
patients who are unaddressed by the current available treatments
with IK-595. I am looking forward to collaborating with this team
on both of these novel targeted oncology programs for patients with
great unmet needs.”
Dr. Sergio Santillana will resign from his role as Chief Medical
Officer upon Dr. Germa’s appointment and will continue to consult
for the Company to ensure a smooth transition of clinical
responsibilities and activities to Dr. Germa. Dr. Manfredi
continued, “We would like to thank Sergio for his dedication and
contributions to Ikena. Dr. Santillana’s leadership was integral to
bringing our programs into the clinic, and we wish him well in his
future endeavors.”
About Ikena OncologyIkena Oncology® is focused
on developing differentiated therapies for patients in need that
target nodes of cancer growth, spread, and therapeutic resistance
in the Hippo and RAS onco-signaling network. The Company’s lead
targeted oncology program, IK-930, is a TEAD1 selective Hippo
pathway inhibitor, a known tumor suppressor pathway that also
drives resistance to multiple targeted therapies. The Company’s
second clinical stage program targets the RAS signaling pathway
with IK-595, a novel MEK-RAF molecular glue. Ikena aims to utilize
their depth of institutional knowledge and breadth of tools to
efficiently develop the right drug using the right modality for the
right patient. To learn more, visit www.ikenaoncology.com or follow
us on X and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, implied and express statements
regarding: the timing and advancement of our targeted oncology
programs, including the timing of updates; our expectations
regarding the therapeutic benefit of our targeted oncology
programs; our ability to efficiently discover and develop product
candidates; our ability to obtain and maintain regulatory approval
of our product candidates; expectations with respect to year end
cash and projected cash runway; the anticipated results of our
organizational changes; the implementation of our business model;
and strategic plans for our business and product candidates. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of our targeted oncology programs; our expectations
regarding the therapeutic benefit of our targeted oncology
programs; our ability to efficiently discover and develop product
candidates; the implementation of our business model, and strategic
plans for our business and product candidates, the sufficiency of
the Company’s capital resources to fund operating expenses and
capital expenditure requirements and the period in which such
resources are expected to be available, and other factors discussed
in the “Risk Factors” section of Ikena’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2023, which is on file
with the Securities and Exchange Commission (SEC), as updated by
any subsequent SEC filings. We caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date they are made. We disclaim any obligation to publicly
update or revise any such statements to reflect any change in
expectations or in events, conditions or circumstances on which any
such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.
Investor Contact:Rebecca CohenIkena
Oncologyrcohen@ikenaoncology.com
Media Contact:Luke ShiploLifeSci
Communicationslshiplo@lifescicomms.com
Ikena Oncology (NASDAQ:IKNA)
過去 株価チャート
から 4 2024 まで 5 2024
Ikena Oncology (NASDAQ:IKNA)
過去 株価チャート
から 5 2023 まで 5 2024